+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Treatment, Disease-Modifying Therapies), By End use, By Region, And Segment Forecasts, 2023-2030

  • PDF Icon

    Report

  • 120 Pages
  • June 2023
  • Region: Global
  • Grand View Research
  • ID: 4621761
Description Jump to:

The global Huntington’s disease treatment market size is expected to reach USD 1,871.2 million by 2030. The market is expected to expand at a CAGR of 23.20% from 2023 to 2030. This growth is due to high R&D investments for new product development, research collaboration, and the high HD burden in western countries. Huntington's disease is a rare inherited neurodegenerative disease that affects several generations. It affects people between the ages of 30 and 50, impairing their capacity to work, care for their families, and, eventually, complete daily tasks.

The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. As a result, the prevalence of enlarged repetitions in the general population may be greater than expected. The Asian population has consistently had a lower prevalence, while Europe, North America, and Australia have a higher prevalence.

The key players, such as Neurocrine Biosciences, Inc. and Azevan Pharmaceuticals, Inc., are focusing on research and development of symptomatic therapies for HD. Azevan Pharmaceuticals is developing SRX246 as an experimental drug to treat neuropsychiatric symptoms in Huntington's disease. SRX246 is a drug that works by blocking the vasopressin 1a (V1a) receptor in the brain. In the neurological system, V1a receptor is the major vasopressin receptor. SRX246 works by inhibiting the V1a receptor, restricting vasopressin from attaching to the receptor, and generating irritable and aggressive behavior, which is seen in Huntington's disease patients.

However, currently approved drugs provide symptomatic and palliative care and do not target the underlying cause of the disease. While medications can decrease the severity of symptoms, they are often associated with adverse effects such as somnolence, gait issues, dysphagia, and apathy, which can have serious impacts on a patient’s quality of life. Given the lack of a cure for the disease, it is critical to evaluate how Health-related Quality of Life (HRQOL) is affected in these patients. HD patients in early to middle stages of the disease need coordinated multidisciplinary healthcare services, including assessment of cognitive function and counseling.

Drug development for HD has faced significant obstacles as several therapies have failed to demonstrate efficacy or were associated with significant toxicity. Vaccinex Inc.'s phase II trial of Pepinemab failed to satisfy pre-specified co-primary endpoints in patients with early manifest and prodromal HD, in September 2020. The two co-primary endpoints-a family of two cognitive evaluations from the Huntington's disease Cognitive Assessment Battery and Clinical Global Impression of Change (CGIC)-did not attain statistical significance in the early manifestation population in the SIGNAL study.

Huntington’s Disease Treatment Market Report Highlights

  • The symptomatic treatment segment accounted for the largest revenue share in 2022 owing to the product availability and patent protection. Disease-modifying therapies is anticipated to be the fastest-growing segment over the forecast years due to the entry of SAGE-718, and Cellavita-HD
  • Companies are now focusing on the development of treatments that can be injected directly into the brain to directly inhibit the formation of mutant HTT protein, instead of targeting the mutant protein
  • Drugs with novel targets in early-phase development include Cellavita and Azidus Brazil’s Cellavita HD (stem cell therapy), Sangamo Therapeutics, Inc. mHTT ZFP (zinc finger protein), and UniQure’s AMT-130 (gene therapy)
  • North America held the highest revenue share in 2022 and is expected to dominate the market over the forecast period due to better reimbursement facilities and the high burden of HD in the U.S. and Canada

Table of Contents

Chapter 1. Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definitions
1.1.1.1 Treatment Segment
1.1.1.2 End Use Segment
1.2 Regional Scope
1.3 Estimates And Forecast Timeline
1.4 Objectives
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List Of Secondary Sources
1.11 List Of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation And Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends And Outlook
3.4. Market Dynamics
3.4.1. Market Drivers Analysis
3.4.1.1. Strong Product Pipeline
3.4.1.2. Disease Burden Of Huntington’s In Developed Countries
3.4.2. Market Restraint Analysis
3.4.2.1. Significant Challenges And Unmet Needs In Huntington’s Disease Treatment
3.4.2.2. High Failure Rate In Clinical Trials
3.5. Business Environment Analysis
3.5.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.5.2. Porter’s Five Forces Analysis
Chapter 4. Product Business Analysis
4.1 Huntington’s Disease Treatment Market: Treatment Movement Analysis
4.2 Symptomatic Treatment
4.2.1 Symptomatic Treatment Market, 2018 - 2030 (USD Million)
4.3 Disease-Modifying Therapies
4.3.1 Disease-Modifying Therapies Market, 2018 - 2030 (USD Million)
Chapter 5. End User Business Analysis
5.1 Huntington’s Disease Treatment Market: End User Movement Analysis
5.1.1 Hospital Pharmacy
5.1.1.1 Hospital Pharmacy market estimates and forecast, 2018 - 2030
5.1.2 Retail Pharmacy
5.1.2.1 Retail Pharmacy market estimates and forecast, 2018 - 2030
5.1.3 E-Commerce
5.1.3.1 E-Commerce market estimates and forecast, 2018 - 2030
Chapter 6. Regional Business Analysis
6.1. Huntington’s Disease Treatment Market Share By Region, 2022 & 2030
6.2. North America
6.2.1. SWOT Analysis
6.2.2. North America Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.2.3. U.S.
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Competitive Scenario
6.2.3.4. Regulatory Framework
6.2.3.5. Reimbursement Scenario
6.2.3.6. U.S. Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.2.4. Canada
6.2.4.1. Key Country Dynamics
6.2.4.2. Target Disease Prevalence
6.2.4.3. Competitive Scenario
6.2.4.4. Regulatory Framework
6.2.4.5. Reimbursement Scenario
6.2.4.6. Canada Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.3. Europe
6.3.1. SWOT Analysis
6.3.2. Europe Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.3.3. Germany
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Competitive Scenario
6.3.3.4. Regulatory Framework
6.3.3.5. Reimbursement Scenario
6.3.3.6. Germany Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.3.4. UK
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. Competitive Scenario
6.3.4.4. Regulatory Framework
6.3.4.5. Reimbursement Scenario
6.3.4.6. UK Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.3.5. France
6.3.5.1. Key Country Dynamics
6.3.5.2. Target Disease Prevalence
6.3.5.3. Competitive Scenario
6.3.5.4. Regulatory Framework
6.3.5.5. Reimbursement Scenario
6.3.5.6. France Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.3.6. Italy
6.3.6.1. Key Country Dynamics
6.3.6.2. Target Disease Prevalence
6.3.6.3. Competitive Scenario
6.3.6.4. Regulatory Framework
6.3.6.5. Reimbursement Scenario
6.3.6.6. Italy Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.3.7. Spain
6.3.7.1. Key Country Dynamics
6.3.7.2. Target Disease Prevalence
6.3.7.3. Competitive Scenario
6.3.7.4. Regulatory Framework
6.3.7.5. Reimbursement Scenario
6.3.7.6. Spain Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.3.8. Denmark
6.3.8.1. Key Country Dynamics
6.3.8.2. Target Disease Prevalence
6.3.8.3. Competitive Scenario
6.3.8.4. Regulatory Framework
6.3.8.5. Reimbursement Scenario
6.3.8.6. Denmark Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.3.9. Sweden
6.3.9.1. Key Country Dynamics
6.3.9.2. Target Disease Prevalence
6.3.9.3. Competitive Scenario
6.3.9.4. Regulatory Framework
6.3.9.5. Reimbursement Scenario
6.3.9.6. Sweden Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.3.10. Norway
6.3.10.1. Key Country Dynamics
6.3.10.2. Target Disease Prevalence
6.3.10.3. Competitive Scenario
6.3.10.4. Regulatory Framework
6.3.10.5. Reimbursement Scenario
6.3.10.6. Norway Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.4. Asia Pacific
6.4.1. SWOT Analysis
6.4.2. Asia Pacific Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Competitive Scenario
6.4.3.4. Regulatory Framework
6.4.3.5. Reimbursement Scenario
6.4.3.6. Japan Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.4.4. China
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Competitive Scenario
6.4.4.4. Regulatory Framework
6.4.4.5. Reimbursement Scenario
6.4.4.6. China Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.4.5. India
6.4.5.1. Key Country Dynamics
6.4.5.2. Target Disease Prevalence
6.4.5.3. Competitive Scenario
6.4.5.4. Regulatory Framework
6.4.5.5. Reimbursement Scenario
6.4.5.6. India Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.4.6. South Korea
6.4.6.1. Key Country Dynamics
6.4.6.2. Target Disease Prevalence
6.4.6.3. Competitive Scenario
6.4.6.4. Regulatory Framework
6.4.6.5. Reimbursement Scenario
6.4.6.6. South Korea Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.4.7. Australia
6.4.7.1. Key Country Dynamics
6.4.7.2. Target Disease Prevalence
6.4.7.3. Competitive Scenario
6.4.7.4. Regulatory Framework
6.4.7.5. Reimbursement Scenario
6.4.7.6. Australia Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.4.8. Thailand
6.4.8.1. Key Country Dynamics
6.4.8.2. Target Disease Prevalence
6.4.8.3. Competitive Scenario
6.4.8.4. Regulatory Framework
6.4.8.5. Reimbursement Scenario
6.4.8.6. Thailand Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.5. Latin America
6.5.1. SWOT Analysis
6.5.2. Latin America Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.5.3. Brazil
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Competitive Scenario
6.5.3.4. Regulatory Framework
6.5.3.5. Reimbursement Scenario
6.5.3.6. Brazil Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.5.4. Mexico
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Competitive Scenario
6.5.4.4. Regulatory Framework
6.5.4.5. Reimbursement Scenario
6.5.4.6. Mexico Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.5.5. Argentina
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Competitive Scenario
6.5.5.4. Regulatory Framework
6.5.5.5. Reimbursement Scenario
6.5.5.6. Argentina Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.6. MEA
6.6.1. SWOT Analysis
6.6.2. MEA Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.6.3. South Africa
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Competitive Scenario
6.6.3.4. Regulatory Framework
6.6.3.5. Reimbursement Scenario
6.6.3.6. South Africa Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.6.4. Saudi Arabia
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Competitive Scenario
6.6.4.4. Regulatory Framework
6.6.4.5. Reimbursement Scenario
6.6.4.6. Saudi Arabia Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.6.5. UAE
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Competitive Scenario
6.6.5.4. Regulatory Framework
6.6.5.5. Reimbursement Scenario
6.6.5.6. UAE Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
6.6.6. Kuwait
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Prevalence
6.6.6.3. Competitive Scenario
6.6.6.4. Regulatory Framework
6.6.6.5. Reimbursement Scenario
6.6.6.6. Kuwait Huntington’s Disease Treatment Market, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1 Company Categorization
7.2 Strategy Mapping
7.1.1. New Product Launch
7.1.2. Partnerships
7.1.3. Acquisition
7.1.4. Collaboration
7.1.5. Funding
7.3 Key Company Market Share Analysis, 2022
7.4 Company Profiles
7.4.1 H. LUNDBECK A/S
7.4.1.1 Company overview
7.4.1.2 Financial performance
7.4.1.3 Product benchmarking
7.4.1.4 Strategic Initiatives
7.4.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
7.4.2.1 Company overview
7.4.2.2 Financial performance
7.4.2.3 Product benchmarking
7.4.2.4 Strategic Initiatives
7.4.3 BAUSCH HEALTH COMPANIES INC.
7.4.3.1 Company overview
7.4.3.2 Financial performance
7.4.3.3 Product benchmarking
7.4.3.4 Strategic Initiatives
7.4.4 HETERO
7.4.4.1 Company overview
7.4.4.2 Product benchmarking
7.4.4.3 Strategic Initiatives
7.4.5 LUPIN
7.4.5.1 Company overview
7.4.5.2 Financial performance
7.4.5.3 Product benchmarking
7.4.5.4 Strategic Initiatives
7.4.6 HIKMA PHARMACEUTICALS PLC
7.4.6.1 Company overview
7.4.6.2 Financial performance
7.4.6.3 Product benchmarking
7.4.6.4 Strategic Initiatives
7.4.7 DR. REDDY’S LABORATORIES LTD.
7.4.7.1 Company overview
7.4.7.2 Financial performance
7.4.7.3 Product benchmarking
7.4.7.4 Strategic Initiatives
7.4.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
7.4.8.1 Company overview
7.4.8.2 Financial performance
7.4.8.3 Product benchmarking
7.4.8.4 Strategic Initiatives
List of Tables
Table 1: List of Secondary Sources
Table 2: List of Abbreviations
Table 3: Global Huntington’s Disease Treatment Market, by Region, 2018-2030 (USD Million)
Table 4: Global Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 5: Global Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 6: Global Huntington’s Disease Treatment Market, by Region, 2018-2030 (USD Million)
Table 7: North America Huntington’s Disease Treatment Market, by Country, 2018-2030 (USD Million)
Table 8: North America Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 9: North America Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 10: U.S. Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 11: U.S. Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 12: Canada Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 13: Canada Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 14: Europe Huntington’s Disease Treatment Market, by Country, 2018-2030 (USD Million)
Table 15: Europe Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 16: Europe Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 17: Germany Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 18: Germany Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 19: UK Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 20: UK Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 21: France Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 22: France Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 23: Italy Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 24: Italy Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 25: Spain Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 26: Spain Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 27: Denmark Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 28: Denmark Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 29: Sweden Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 30: Sweden Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 31: Norway Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 32: Norway Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 33: Asia Pacific Huntington’s Disease Treatment Market, by Country, 2018-2030 (USD Million)
Table 34: Asia Pacific Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 35: Asia Pacific Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 36: China Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 37: China Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 38: Japan Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 39: Japan Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 40: India Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 41: India Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 42: South Korea Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 43: South Korea Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 44: Australia Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 45: Australia Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 46: Thailand Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 47: Thailand Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 48: Latin America Huntington’s Disease Treatment Market, by Country, 2018-2030 (USD Million)
Table 49: Latin America Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 50: Latin America Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 51: Brazil Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 52: Brazil Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 53: Mexico Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 54: Mexico Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 55: Argentina Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 56: Argentina Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 57: Middle East & Africa Huntington’s Disease Treatment Market, by Country, 2018-2030 (USD Million)
Table 58: Middle East & Africa Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 59: Middle East & Africa Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 60: South Africa Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 61: South Africa Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 62: Saudi Arabia Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 63: Saudi Arabia Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 64: UAE Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 65: UAE Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
Table 66: Kuwait Huntington’s Disease Treatment Market, by Treatment, 2018-2030 (USD Million)
Table 67: Kuwait Huntington’s Disease Treatment Market, by End use, 2018-2030 (USD Million)
List of Figures
Fig. 1: Market Research Process
Fig. 2: Information Procurement
Fig. 3: Primary Research Pattern
Fig. 4: Market Research Approaches
Fig. 5: Value Chain - Based Sizing & Forecasting
Fig. 6: Market Formulation & Validation
Fig. 7: Huntington’s Disease Treatment Market Segmentation
Fig. 8: Market Snapshot, 2022
Fig. 9: Market Trends & Outlook
Fig. 10: Market Driver Relevance Analysis (Current & Future Impact)
Fig. 11: Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 12: SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13: Porter’s Five Forces Analysis
Fig. 14: Global Huntington’s Disease Treatment Market: by Treatment Movement Analysis
Fig. 15: Global Huntington’s Disease Treatment Market, for Symptomatic treatment, 2018-2030 (USD Million)
Fig. 16: Global Huntington’s Disease Treatment Market, for Disease - modifying therapies, 2018-2030 (USD Million)
Fig. 17: Global Huntington’s Disease Treatment Market: End use Movement Analysis
Fig. 18: Global Huntington’s Disease Treatment Market, for Pharmaceutical & Biotechnology Companies, 2018-2030 (USD Million)
Fig. 19: Global Huntington’s Disease Treatment Market, for Hospital pharmacy, 2018-2030 (USD Million)
Fig. 20: Global Huntington’s Disease Treatment Market, for Retail pharmacy, 2018-2030 (USD Million)
Fig. 21: Global Huntington’s Disease Treatment Market, for E - commerce, 2018-2030 (USD Million)
Fig. 22: Regional Marketplace: Key Takeaways Huntington’s Disease Treatment Market, Region 2018-2030 (USD Million)
Fig. 23: Huntington’s Disease Treatment Market :Regional Outlook, 2022 & 2030 2018-2030 (USD Million)
Fig. 24: North America Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 25: U.S. Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 26: Canada Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 27: Europe Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 28: Germany Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 29: UK Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 30: France Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 31: Italy Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 32: Spain Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 33: Denmark Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 34: Sweden Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 35: Norway Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 36: Asia Pacific Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 37: Japan Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 38: China Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 39: India Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 40: Australia Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 41: South Korea Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 42: Thailand Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 43: Latin America Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 44: Brazil Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 45: Mexico Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 46: Argentina Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 47: Middle East and Africa Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 48: South Africa Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 49: Saudi Arabia Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 50: UAE Huntington’s Disease Treatment Market, 2018-2030 (USD Million)
Fig. 51: Kuwait Huntington’s Disease Treatment Market, 2018-2030 (USD Million)

Companies Mentioned

  • H. Lundbeck A/S
  • Teva Pharmaceutical Industries Ltd.
  • Bausch Health Companies Inc.
  • Hetero
  • Lupin
  • Hikma Pharmaceuticals PLC
  • Dr. Reddy’s Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Huntington's Disease Treatment Market Report by Type, Drug Type, Age, Distribution Channel, End User, and Region 2024-2032 - Product Image

Huntington's Disease Treatment Market Report by Type, Drug Type, Age, Distribution Channel, End User, and Region 2024-2032

  • Report
  • 135 Pages
  • Global
From
Huntington's Disease Treatment Market Forecasts from 2023 to 2028 - Product Image

Huntington's Disease Treatment Market Forecasts from 2023 to 2028

  • Report
  • 145 Pages
  • Global
From
Huntington`s Disease Therapeutics - Global Strategic Business Report - Product Image

Huntington`s Disease Therapeutics - Global Strategic Business Report

  • Report
  • 172 Pages
  • Global
From
Huntington's Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Huntington's Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 180 Pages
  • Global
From
Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Drug Type (Approved Drugs (Tetrabenazine and Deutetrabenazine) and Offlabel Drugs), By Distribution Channel, By Age, By Regional Outlook and Forecast, 2024 - 2031 - Product Image

Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Drug Type (Approved Drugs (Tetrabenazine and Deutetrabenazine) and Offlabel Drugs), By Distribution Channel, By Age, By Regional Outlook and Forecast, 2024 - 2031

  • Report
  • 266 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.